期刊文献+

Janus激酶抑制药tofacitinib 被引量:1

下载PDF
导出
摘要 Janus激酶活化的信号传导及转录激活因子(Janus-activatedkinaseSingaltransducersandactiva—torsoftranscription,JAK—STAT)是近年来新发现的一条与细胞因子密切相关的细胞内信号传导通路,参与细胞的增殖、分化、凋亡以及免疫调节等许多重要的生物学过程。Janus激酶是一种非受体型酪氨酸蛋白激酶。有4个家族成员,分别是JAKl、JAK2、TYK2和JAK3。前3者广泛存在于各种组织和细胞中,而JAK3仅存在于骨髓和淋巴系统。
机构地区 开滦总医院
出处 《药物流行病学杂志》 CAS 2013年第11期624-626,共3页 Chinese Journal of Pharmacoepidemiology
  • 相关文献

参考文献11

  • 1De Lartigue J. Tofacitinib for the treatment of moderate tosevere rheumatoid arthritis[ J] . Drugs Today (Bare) ,2012,48(8) : 533-543.
  • 2Ghoreschi K, Jesson MI, Li X, et al. Modulation of innateand adaptive immune responses by tofacitinib ( CP-690,550)[J]. J Immunol 2011,186(7) : 4234-4243.
  • 3Labranche TP, Jesson MI, Radi ZA, et al. JAK inhibitionwith tofacitinib suppresses arthritic joint structural damagethrough decreased RANKL production [ J ] . Arthritis Rheum,2012 , 64(11): 3531-3542.
  • 4Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib ( CP- 690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone [ J ]. Arthritis Rheum,2012, 64(4): 970-951.
  • 5http://www. rxlist. com/xeljanz-drug. htm,2012-11-15/2013-01-21.
  • 6Fleischmann R,Cutolo M,Genovese MC, et al. Phase II i,dose-ranging study of the oral JAK inhibitor tofacitinib ( CP-690 ,550) or adalimumab monotherapy versus placebo in pa-tients with active rheumatoid arthritis with an inadequate re-sponse to disease-modifying antirheumatic drugs[ J]. Arthri-tis Rheum^2012^ 64(3) : 617-629.
  • 7Fleischmann R,Kremer J,Cush J,et al. Placebo-controlledtrial of tofacitinib monotherapy in rheumatoid arthritis[ J] . NEngl J Med,2012, 367(6) : 495-507.
  • 8Van Vollenhoven RF,Fleischmann R, Cohen S,et al. To-facitinib or adalimumab versus placebo in rheumatoid arthri-tis[J]. N Engl J Med, 2012,367 (6) : 508-519.
  • 9Papp KA,Menter A,Strober B,et al. Efficacy and safety oftofacitinib, an oral Janus kinase inhibitor, in the treatmentof psoriasis : a Phase 2b randomized placebo-controlled dose-ranging study[ J]. Br J Dermatoly20\2, 167(3) ; 668-677.
  • 10Sandbom WJ, Ghosh S, Panes J, et al. Tofacitinib, an oralJanus kinase inhibitor,in active ulcerative colitis [ J ]. NEngl J Med,2012, 367(7) : 616-624.

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部